*Sponsored
Market Crux Announces Coverage On Aclarion, Inc. (Nasdaq: ACON) Starting
This Morning—Thursday December 4, 2025
Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
Get (ACON) On Your Screen While It's Still Early…
December 4, 2025
10 Minutes to Go | See Why (ACON) is in the Top Spot on Our Radar Ahead of the Bell Dear Reader, Every year, more than 635,000 Americans undergo spinal fusion surgery—yet close to half walk away without lasting relief. Not because the procedures fall short, but because identifying the exact disc responsible for pain remains one of the most persistent challenges in spine care—a challenge tied to a $135B annual burden in the U.S. healthcare system. Traditional imaging can show structural issues, but it can't reliably pinpoint the true source of symptoms before the first incision is made. Aclarion, Inc. (Nasdaq: ACON) is attempting to change that. Its Nociscan platform—an AI-driven, non-invasive diagnostic built on magnetic resonance spectroscopy—brings chemical-level clarity to a problem that has long stalled patient outcomes. It's the emergence of this technology, and the size of the market it targets, that puts (ACON) at the top of our watchlist this morning—Thursday, December 4, 2025.
But keep in mind, (ACON) has less than 700K shares listed in its public float. When floats are this small, the potential exists for big moves if demand begins to shift. And Ascendiant Capital Markets analyst Lucas Ward has set a $23 target on (ACON), which suggests over 250% upside potential from its recent $6.35 range. 
Keep reading to see why (ACON) just landed on our radar. Game-Changing Technology in a Massive Healthcare Market
Aclarion, Inc. (Nasdaq: ACON) has positioned itself at the convergence of artificial intelligence and precision medicine with Nociscan—a non-invasive platform that uses magnetic resonance spectroscopy (MRS) to pinpoint exactly which intervertebral discs are generating chronic low back pain. This technology is supported by a deep intellectual property foundation, including 24 issued U.S. patents, 17 international patents, and an exclusive worldwide UCSF license covering disc biomarker identification. This creates meaningful barriers to competition as advanced diagnostic solutions continue shifting toward objective chemical analysis. The market potential is staggering. 
Low back and neck pain costs the U.S. healthcare system $135B annually, with 266M patients worldwide suffering from degenerative spine disease and chronic pain. In the United States alone, 16M people experience chronic low back pain each year. Traditional MRI scans can reveal structural damage but cannot identify which specific disc is causing pain. Provocative discography—the current diagnostic standard—is invasive, intensely painful for patients, and relies on subjective patient feedback during the procedure. Aclarion's (Nasdaq: ACON) Nociscan platform transforms this paradigm. By measuring chemical biomarkers including acidic pain markers—lactic acid, alanine, and propionate—the technology delivers objective, disc-by-disc analysis at half the cost of discography with zero invasiveness. Clinical validation is already emerging. The Gornet study published in European Spine Journal demonstrated that 97% of patients improved when all Nociscan-positive discs were treated, versus only 54% improvement when a Nociscan-positive disc was left untreated. These results remained durable at 2-year follow-up data. Commercial Traction Accelerating Across Key Markets
While Aclarion, Inc. (Nasdaq: ACON) remains in early-stage commercialization, momentum is building in ways that could significantly accelerate adoption curves. The company has secured coverage from three of the top four private medical insurers in the United Kingdom—representing approximately 5.2M covered lives. Private payment and insurance comprise 72% of UK private hospital revenue, and The London Clinic is now executing a comprehensive commercial launch strategy to drive physician adoption. In the U.S. market, Aclarion (Nasdaq: ACON) has established Category III CPT codes through the American Medical Association, creating the foundation for future reimbursement pathways. The company is actively engaging key opinion leaders at premier institutions including Johns Hopkins, UCSF, and Northwestern. The data confirms accelerating traction: Q3 2025 Nociscan scan volumes surged 89% year-over-year, according to Ascendiant Capital Markets analyst Lucas Ward. While Q3 revenue of $18,942 remains modest in absolute terms, the growth trajectory indicates expanding clinical adoption as coverage decisions and validation studies progress. New Leadership Drives U.S. Expansion
(ACON) announced the appointment of Jason Brosniak as Commercial Director for the Eastern U.S., bringing more than 20 years of commercial leadership in high-growth MedTech, including roles at companies later acquired by Boston Scientific and Medtronic. Brosniak has a strong background launching breakthrough technologies in spine, neurosurgery, and pain management—directly aligning with Nociscan's target market. His hire marks another key commercial milestone as Aclarion scales adoption, expands payer engagement, and responds to growing clinician demand driven by real-world evidence and the national CLARITY trial. This appointment follows the recent addition of a UK Commercial Director, highlighting the Company's accelerating push to expand access for patients suffering from chronic low back pain worldwide. A High-Impact Trial Milestone
The most significant near-term value driver for Aclarion, Inc. (Nasdaq: ACON) is the CLARITY pivotal trial—a randomized, controlled, multi-site study comparing surgical outcomes when physicians have Nociscan data versus standard care without it. Dr. Nicholas Theodore, Director of the Neurosurgical Spine Center at Johns Hopkins Medicine, serves as Principal Investigator. The study enrolled its first patient in June 2025 at UHealth - University of Miami, and Aclarion (Nasdaq: ACON) anticipates initial interim results in Q2 2026. Eight sites are now qualified for the 300-patient study, which is fully funded at approximately $4.6M in total costs. If results validate Nociscan's clinical utility in improving surgical outcomes, this data could be transformative for broader payer coverage decisions. The evidence pipeline extends beyond CLARITY. Aclarion (Nasdaq: ACON) currently has seven ongoing clinical trials and eight peer-reviewed publications, with over 250 patients studied to date across its clinical program. Numbers That Tell the Story
Perhaps the most compelling aspect of Aclarion, Inc. (Nasdaq: ACON) from a risk-reward perspective is the company's financial strength relative to current market capitalization. As of October 14, 2025, Aclarion (Nasdaq: ACON) held $13.3M in cash—representing $15.11 per share on a fully diluted basis. The company subsequently raised approximately $2M in net proceeds via a registered direct offering in October 2025. With projected annual burn of $7-8M, Lucas Ward at Ascendiant calculates a cash runway extending well into 2027. The capital structure is remarkably clean: zero debt, no preferred shares, and no near-term warrant overhang. The company maintains full Nasdaq compliance, meeting both minimum bid price and shareholder equity requirements. With current market capitalization in the $4–6M range and net cash value estimated at roughly $17 per share, Ascendiant's analysis suggests that Aclarion is effectively hovering at levels that resemble a call option on the ongoing commercialization of Nociscan. 7 Reasons Why (Nasdaq: ACON) Is Topping Our Watchlist
This Morning—Thursday December 4, 2025
1. Extremely Limited Float: With less than 700K shares in the public float per Yahoo data, (Nasdaq: ACON) has the type of limited share availability that can lead to significant price moves when demand shifts.
2. Analyst Target: Ascendiant Capital Markets analyst Lucas Ward maintains a $23 target on (Nasdaq: ACON), which suggests over 250% upside potential from recent levels. 3. Trending Below Net Cash Value: At $13.3M cash on hand against a $4-6M market cap, Aclarion (Nasdaq: ACON) offers more than $17 per share in net cash while still well below that threshold—an unusual value proposition. 4. Clear Clinical Catalyst Timeline: CLARITY trial interim results expected Q2 2026 provide a defined milestone that could validate Aclarion's (Nasdaq: ACON) clinical thesis and potentially accelerate payer adoption decisions. 5. Commercial Momentum Gaining Speed: Q3 scan volumes up 89% year-over-year, combined with UK private insurance coverage from three top-tier payers, demonstrates that sophisticated healthcare organizations see value in the technology. 6. Robust Intellectual Property Protection: 24 issued U.S. patents and 17 issued international patents, including an exclusive worldwide UCSF license for disc biomarkers, create meaningful barriers to competition around Aclarion's (Nasdaq: ACON) core platform. 7. Addressing Healthcare's Largest Cost Center: The $135B U.S. market for low back and neck pain represents one of healthcare's most significant expense categories, with 266M patients suffering globally—providing substantial long-term expansion potential. Get (ACON) On Your Screen While It's Still Early…
Aclarion, Inc. (Nasdaq: ACON) presents an exciting setup for those focused on transformative healthcare technologies trading at significant discounts to intrinsic value. The company combines breakthrough diagnostic technology addressing a massive market, accelerating commercial adoption, and adequate capital to reach pivotal milestones—all while trading below net cash value. With an analyst projecting over 250% upside, an extremely limited float that could witness the potential for big swings and clinical catalysts approaching, (ACON) warrants very close attention right now. (ACON) is set to lead our watchlist first thing this morning. Keep a lookout for my next update—it could be here any moment. Gary Silver
Managing Editor,
Market Crux | 
0 التعليقات:
إرسال تعليق